{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:09:06Z","timestamp":1793423346339,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.074","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T21:16:26Z","timestamp":1557436586000},"page":"3326-3334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":445,"title":["mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials"],"prefix":"10.1016","volume":"37","author":[{"given":"Robert A.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainard","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilcar","family":"(Mick) Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5316-5373","authenticated-orcid":false,"given":"Mike","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u04e6rn","family":"Almarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari S.","family":"Pujar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Laska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Zaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2019.04.074_b0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7774\/cevr.2014.3.2.140","article-title":"Zoonotic infections with avian influenza A viruses and vaccine preparedness: a game of \u201cmix and match\u201d","volume":"3","author":"Pascua","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"issue":"7510","key":"10.1016\/j.vaccine.2019.04.074_b0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature13443","article-title":"Receptor binding by H10 influenza viruses","volume":"511","author":"Vachieri","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.vaccine.2019.04.074_b0015","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.vaccine.2019.04.074_b0020","first-page":"460","article-title":"Human cases of influenza at the human-animal interface, January 2015-April 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.074_b0025","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3201\/eid2308.170600","article-title":"Human infection with highly pathogenic avian influenza A(H7N9) virus","volume":"23","author":"Ke","year":"2017","journal-title":"China. Emerg Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2019.04.074_b0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra1208802","article-title":"Pandemic preparedness and response\u2013lessons from the H1N1 influenza of 2009","volume":"370","author":"Fineberg","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.074_b0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3201\/eid1903.120394","article-title":"Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009\u20132010","volume":"19","author":"Borse","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.074_b0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jval.2011.07.014","article-title":"Modeling the effects of H1N1 influenza vaccine distribution in the United States","volume":"15","author":"Larson","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.074_b0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1473-3099(14)70999-5","article-title":"The development of global vaccine stockpiles","volume":"15","author":"Yen","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.074_b0050","first-page":"105","article-title":"Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"6357","key":"10.1016\/j.vaccine.2019.04.074_b0055","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.357.6357.1222","article-title":"Why is the flu vaccine so mediocre?","volume":"357","author":"Cohen","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.074_b0060","doi-asserted-by":"crossref","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","article-title":"A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.074_b0065","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.04.074_b0070","unstructured":"US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. (https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm091990.pdf)."},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.074_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika Virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.04.074_b0080","unstructured":"US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. (http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm078932.pdf)."},{"key":"10.1016\/j.vaccine.2019.04.074_b0085","unstructured":"US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. (https:\/\/wayback.archive-it.org\/7993\/20180124164056\/https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-bio-gen\/documents\/document\/ucm091977.pdf)."},{"key":"10.1016\/j.vaccine.2019.04.074_b0090","unstructured":"Webster R, Cox N, Stohr K. World Health Organization Manual on Animal Influenza Diagnosis and Surveillance. (http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/whocdscsrncs20025rev.pdf)."},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.074_b0095","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: self-adjuvanted RNActive\u00ae vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.074_b0100","unstructured":"The European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf)."},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.074_b0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4161\/hv.24939","article-title":"Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design","volume":"9","author":"De Groot","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.074_b0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3201\/eid2002.131094","article-title":"Human antibody responses to avian influenza A(H7N9) virus, 2013","volume":"20","author":"Guo","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1898","key":"10.1016\/j.vaccine.2019.04.074_b0115","article-title":"Antibody immunity induced by H7N9 avian influenza vaccines: evaluation criteria, affecting factors, and implications for rational vaccine design","volume":"8","author":"Hu","year":"2017","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.074_b0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.074_b0125","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.074_b0130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4161\/hv.28618","article-title":"A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59\u00ae-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration","volume":"10","author":"Della Cioppa","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"25","key":"10.1016\/j.vaccine.2019.04.074_b0135","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","author":"Greenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.vaccine.2019.04.074_b0140","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.vaccine.2016.06.064","article-title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Moa","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.074_b0145","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.074_b0150","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/655830","article-title":"AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age","volume":"51","author":"Roman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2019.04.074_b0155","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.074_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.04.074_b0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","article-title":"Immunogenicity and protective efficacy of influenza vaccination","volume":"103","author":"Hannoun","year":"2004","journal-title":"Virus Res"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.074_b0170","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"issue":"20","key":"10.1016\/j.vaccine.2019.04.074_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01202-17","article-title":"Inactivated H7 influenza virus vaccines protect mice despite inducing only low levels of neutralizing antibodies","volume":"91","author":"Kamal","year":"2017","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.074_b0180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/irv.12383","article-title":"An overview of the regulation of influenza vaccines in the United States","volume":"10","author":"Weir","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"issue":"1539","key":"10.1016\/j.vaccine.2019.04.074_b0185","article-title":"Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.074_b0190","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"issue":"10101","key":"10.1016\/j.vaccine.2019.04.074_b0195","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:44Z","timestamp":1759401164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":39,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305626"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.074","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735757678.793573739","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}